These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 29773429)

  • 1. Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational Study.
    Shacham-Abulafia A; Raanani P; Lavie D; Volchek Y; Ram R; Helman I; Shargian L; Gourevitch A; Chubar E; Ratzon R; Rozovski U
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):e295-e301. PubMed ID: 29773429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
    Devos T; Havelange V; Theunissen K; Meers S; Benghiat FS; Gadisseur A; Vanstraelen G; Vellemans H; Bailly B; Granacher N; Lewalle P; De Becker A; Van Eygen K; Janssen M; Triffet A; Vrelust I; Deeren D; Mazure D; Bekaert J; Beck M; Selleslag D
    Ann Hematol; 2021 Jul; 100(7):1723-1732. PubMed ID: 33942128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.
    Heiblig M; Rea D; Chrétien ML; Charbonnier A; Rousselot P; Coiteux V; Escoffre-Barbe M; Dubruille V; Huguet F; Cayssials E; Hermet E; Guerci-Bresler A; Amé S; Sackmann-Sala L; Roy L; Sobh M; Morisset S; Etienne G; Nicolini FE
    Exp Hematol; 2018 Nov; 67():41-48. PubMed ID: 30195076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.
    Cortes JE; Kim DW; Pinilla-Ibarz J; le Coutre P; Paquette R; Chuah C; Nicolini FE; Apperley JF; Khoury HJ; Talpaz M; DiPersio J; DeAngelo DJ; Abruzzese E; Rea D; Baccarani M; Müller MC; Gambacorti-Passerini C; Wong S; Lustgarten S; Rivera VM; Clackson T; Turner CD; Haluska FG; Guilhot F; Deininger MW; Hochhaus A; Hughes T; Goldman JM; Shah NP; Kantarjian H;
    N Engl J Med; 2013 Nov; 369(19):1783-96. PubMed ID: 24180494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management.
    Saussele S; Haverkamp W; Lang F; Koschmieder S; Kiani A; Jentsch-Ullrich K; Stegelmann F; Pfeifer H; La Rosée P; Goekbuget N; Rieger C; Waller CF; Franke GN; le Coutre P; Kirchmair R; Junghanss C
    Acta Haematol; 2020; 143(3):217-231. PubMed ID: 31590170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
    Nicolini FE; Basak GW; Kim DW; Olavarria E; Pinilla-Ibarz J; Apperley JF; Hughes T; Niederwieser D; Mauro MJ; Chuah C; Hochhaus A; Martinelli G; DerSarkissian M; Duh MS; McGarry LJ; Kantarjian HM; Cortes JE
    Cancer; 2017 Aug; 123(15):2875-2880. PubMed ID: 28387926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase.
    Haddad FG; Sasaki K; Nasr L; Short NJ; Kadia T; Dellasala S; Cortes J; Nicolini FE; Issa GC; Jabbour E; Kantarjian H
    Cancer; 2024 Oct; 130(19):3344-3352. PubMed ID: 38804723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ponatinib in refractory Philadelphia chromosome-positive leukemias.
    Cortes JE; Kantarjian H; Shah NP; Bixby D; Mauro MJ; Flinn I; O'Hare T; Hu S; Narasimhan NI; Rivera VM; Clackson T; Turner CD; Haluska FG; Druker BJ; Deininger MW; Talpaz M
    N Engl J Med; 2012 Nov; 367(22):2075-88. PubMed ID: 23190221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting.
    Boddu P; Shah AR; Borthakur G; Verstovsek S; Garcia-Manero G; Daver N; Kadia T; Ravandi F; Jain N; Alhuraiji A; Burger J; Kornblau S; Pierce S; Dellasala S; Jabbour E; Kantarjian H; Cortes J
    Leuk Lymphoma; 2018 Jun; 59(6):1312-1322. PubMed ID: 28972430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial.
    Cortes J; Apperley J; Lomaia E; Moiraghi B; Undurraga Sutton M; Pavlovsky C; Chuah C; Sacha T; Lipton JH; Schiffer CA; McCloskey J; Hochhaus A; Rousselot P; Rosti G; de Lavallade H; Turkina A; Rojas C; Arthur CK; Maness L; Talpaz M; Mauro M; Hall T; Lu V; Srivastava S; Deininger M
    Blood; 2021 Nov; 138(21):2042-2050. PubMed ID: 34407543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Hoy SM
    Drugs; 2014 May; 74(7):793-806. PubMed ID: 24807266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
    Parker WT; Yeung DT; Yeoman AL; Altamura HK; Jamison BA; Field CR; Hodgson JG; Lustgarten S; Rivera VM; Hughes TP; Branford S
    Blood; 2016 Apr; 127(15):1870-80. PubMed ID: 26773037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia.
    Korfi K; Mandal A; Furney SJ; Wiseman D; Somervaille TCP; Marais R
    Ann Oncol; 2015 Jun; 26(6):1180-1187. PubMed ID: 25712455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Narayanan V; Pollyea DA; Gutman JA; Jimeno A
    Drugs Today (Barc); 2013 Apr; 49(4):261-9. PubMed ID: 23616953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safe and effective use of ponatinib in a patient with chronic myeloid leukemia and acute venous thromboembolism on therapeutic anti-coagulation.
    Shomali W; Redmond C; Bogati S; Zimmerman C; Visconte V; Tabarroki A; Kalaycio M; Tiu RV
    Leuk Lymphoma; 2016; 57(1):193-5. PubMed ID: 25942382
    [No Abstract]   [Full Text] [Related]  

  • 17. Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee.
    Januzzi JL; Garasic JM; Kasner SE; McDonald V; Petrie MC; Seltzer J; Mauro M; Croce K; Berman E; Deininger M; Hochhaus A; Pinilla-Ibarz J; Nicolini F; Kim DW; DeAngelo DJ; Kantarjian H; Xu J; Hall T; Srivastava S; Naranjo D; Cortes J
    J Hematol Oncol; 2022 Jan; 15(1):1. PubMed ID: 34991679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
    Cortes JE; Kim DW; Pinilla-Ibarz J; le Coutre PD; Paquette R; Chuah C; Nicolini FE; Apperley JF; Khoury HJ; Talpaz M; DeAngelo DJ; Abruzzese E; Rea D; Baccarani M; Müller MC; Gambacorti-Passerini C; Lustgarten S; Rivera VM; Haluska FG; Guilhot F; Deininger MW; Hochhaus A; Hughes TP; Shah NP; Kantarjian HM
    Blood; 2018 Jul; 132(4):393-404. PubMed ID: 29567798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world outcomes of ponatinib treatment in 724 patients with CML and Ph+ ALL: a post-marketing surveillance study with a special interest in arterial occlusive events in Japan.
    Takahashi N; Kondo T; Ikari Y; Fukumoto Y; Hatake K; Masunari A; Nishibayashi S; Kageyama A; Fukuta Y; Tojo A
    Jpn J Clin Oncol; 2024 Aug; 54(8):930-938. PubMed ID: 38747937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib.
    Breccia M; Efficace F; Iurlo A; Luciano L; Abruzzese E; Gozzini A; Pregno P; Tiribelli M; Rosti G; Minotti G
    Expert Opin Drug Saf; 2018 Jun; 17(6):623-628. PubMed ID: 29845876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.